Illustrative image – not actual.Sun Pharmaceutical Industries has completed acquisition of Japan-based Pola Pharma to strengthen its presence in dermatology segment across the globe. The acquisition of 100 percent shares of Pola Pharma by the company’s wholly-owned subsidiary has been concluded.
Sun Pharmaceutical Industries had entered into a definitive agreement to acquire Pola Pharma which is engaged in research and development, manufacture, sale and distribution of branded, and generic products in Japan.
Pola Pharma’s portfolio mainly comprises dermatology products. It has two manufacturing facilities in Saitama with capabilities to manufacture topical products and injectables.
